Sodium-glucose cotransporter 2(SGLT2) inhibitors intake was linked to a lower risk of developing cardiovascular disease and kidney failure among patients with type 1 diabetes.
‘SGLT2 inhibitors provide significant risk reductions for cardiovascular disease and kidney failure in type 1 diabetic patients.’
Read More..
The study applied the Steno Type 1 Risk Engines, validated prediction models for cardiovascular disease and kidney failure in people with type 1 diabetes, to 3,660 adults with type 1 diabetes who were treated from 2001 to 2016.Read More..
SGLT2 inhibitors usage was linked to a 6.1% lower risk of cardiovascular disease over 5 years and with a 5.3% lower risk of kidney failure.
“In our study, we have shown significant risk reductions for cardiovascular disease and kidney failure with SGLT2 inhibitor treatment in type 1 diabetes,” said lead author Elisabeth Stougaard, PhD, of Steno Diabetes Center, in Copenhagen.
Self-Care Practices in Diabetes Management
Self-care management in a diabetic patient requires skills to make essential changes in routine day-to-day activities for controlling the disease and improving the quality of life in a natural way.
Self-care management in a diabetic patient requires skills to make essential changes in routine day-to-day activities for controlling the disease and improving the quality of life in a natural way.
Advertisement
